Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
7
×
clinical trials
7
×
detroit blog main
detroit top stories
7
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer
fda
abbvie
eli lilly
startups
biogen
bristol-myers squibb
deals
merck
nonalcoholic steatohepatitis
pfizer
What
bio
7
×
roundup
companies
drug
corner
days
growing
ipo
nash
news
week
abbvie’s
acquisitions
ahead
alliance
alzheimer’s
announced
annual
approval
approved
arena’s
assessed
attention
biofourmis
biogen’s
biopharmaceutical
biotech
bounty
bristol
bucks
buy
calls
cancer
celebrate
ceo
chance
changing
cig
collabs
color
Language
unset
Current search:
bio
×
biotech
×
" clinical trials "
×
" detroit top stories "
×
" cancer immunotherapy "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More